The diabetes 'cure' Vertex acquired in its 2019 Semma buyout? It's headed to the clinic
The stem cell-derived therapy at the center of Vertex’s $950 million buyout of Semma Therapeutics in 2019, one that features prominently in the company’s overall cell and gene therapy push, is one step closer to reaching the clinic.
Vertex is expected to launch a Phase I/II trial in the first half of this year after the type 1 diabetes treatment received IND clearance from the FDA on Thursday, the company announced. The program, dubbed VX-880, will be evaluated in type 1 diabetes patients with severe hypoglycemia and those who struggle to perceive the onset of hypoglycemia, like young children.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
